Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146

Evercore ISI Group analyst Gavin Clark-Gartner has maintained an 'Outperform' rating on Mirum Pharmaceuticals (NASDAQ: MIRM) and raised the price target from $135 to $146. This adjustment reflects a positive outlook for the company's performance in the market.